{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-044703","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.680714+00:00","generated_at":"2026-05-30T07:15:05.658517+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan","bullets":["ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.","Net loss $220.5M ($1.27/sh) vs $158.9M ($1.11/sh) in Q3 2023; operating loss $213.4M.","NDA for brensocatib in bronchiectasis on track for Q4 2024; potential US launch mid-2025.","Amended Pharmakon loan adds $150M tranche at 9.60% fixed, maturity extends to Sept 2029.","Ended Q3 with ~$1.5B cash; redeemed $225M convertible notes; raised $371M net via ATM."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-044703","json":"https://secwatch.observer/filing/0001140361-24-044703.json","markdown":"https://secwatch.observer/filing/0001140361-24-044703.md","text":"https://secwatch.observer/filing/0001140361-24-044703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/0001140361-24-044703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/ef20037942_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:15:05.658517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}